Holen Sie sich die Stockscreener-App
0.9203
0.13%
-0.0012
Handel nachbörslich:
.92
-0.0003
-0.03%
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Price to sales forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech | 8-K: Current report - Moomoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech StockWeekly review and sector backdrop - AD HOC NEWS
Oncolytics Biotech | F-10POS: Others - Moomoo
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent - The Globe and Mail
Oncolytics (ONCY) Secures New Patent for Pelareorep Manufacturin - GuruFocus
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Yahoo Finance
Oncolytics receives U.S. patent for pelareorep manufacturing By Investing.com - Investing.com South Africa
Oncolytics Gets US Patent for Pelareorep Manufacturing Process - marketscreener.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics receives U.S. patent for pelareorep manufacturing - Investing.com
Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process - TradingView
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - The Manila Times
New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044 - Stock Titan
US patent shields Oncolytics' pelareorep manufacturing process into 2044 - Stock Titan
Oncolytics Biotech® to Participate in a Panel Presentation at Ca - GuruFocus
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
ONCY: Pivotal data for a novel IV oncolytic virus in GI cancers expected by year-end - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech Strengthens Leadership with New COO, Director - The Globe and Mail
Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO - geneonline.com
Oncolytics appoints Glover to board, promotes McAdory to COO - Investing.com UK
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
Wall Street May Still Be Looking at the Old Oncolytics Story - Barchart.com
Best Compounded Tirzepatide Online Provider (2026) Report Published by Kinross Research - Barchart.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - The IFP
0.23%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):